 Follows multiple Phase II studies of ORPATHYS in Asia including VIKTORY, which reported an 50 objective response rate ORR in gastric cancer patients whose tumors harbor MET amplification Follows multiple Phase II studies of ORPATHYS in Asia including VIKTORY, which reported an 50 objective response rate ORR in gastric cancer patients whose tumors harbor MET amplification 